StockNews.com Upgrades PDS Biotechnology (NASDAQ:PDSB) to Hold

PDS Biotechnology (NASDAQ:PDSB) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Several other research firms also recently issued reports on PDSB. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.25.

PDS Biotechnology Trading Up 0.3 %

Shares of NASDAQ:PDSB opened at $3.20 on Friday. The company has a market capitalization of $117.82 million, a P/E ratio of -2.62 and a beta of 1.93. The business’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $3.27. PDS Biotechnology has a 1 year low of $2.53 and a 1 year high of $6.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company earned ($0.37) EPS. On average, research analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Tempus Wealth Planning LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at about $55,000. Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology during the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at $120,000. Finally, Cubist Systematic Strategies LLC bought a new stake in PDS Biotechnology in the second quarter worth about $146,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.